Proactive Investors - Run By Investors For Investors
Why invest in FUM?
Futura Medical PLC: DEEP DIVE
OVERVIEW

Futura Medical looking ahead to completion of key phase III ED trial

Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year
man with erectile dysfunction
OVERVIEW: FUM The Big Picture
Futura’s ED gel looks to bring spontaneity back to the bedroom
  • Focused on MED2005 ED gel and TPR100 pain relief gel

  • Products based on its DermaSys skin-based drug delivery system

  • MED2005 phase III trial results due by end of year

  • Seeking UK approval for TPR100

 

What it does

Futura Medical PLC (LON:FUM) is developing a portfolio of products for two large markets: sexual health and pain.

All of its products are based around its DermaSys skin-based drug delivery system.

Perhaps the most exciting product is MED2002, Futura’s erectile dysfunction gel which is designed for those men where the current pill-based treatments aren’t appropriate or carry significant side-effects.

It is currently undergoing a Phase III study in Europe, headline data from which is expected by the end of this year.

The company is also working on three pain relief gels: TPR100, TIB200 and SPR300. Each contains a different painkiller or anti-inflammatory.

TPR100, the most advanced gel, contains diclofenac, TIB200 contains ibuprofen and SPR300, which is a potential follow to those two, contains methyl salicylate.

Futura’s most developed product is CSD500, a condom that is coated in an erectogenic gel which helps men maintain firmer erection for longer.

The condoms were launched in Saudi Arabia last year and more than a million have been sold, but without a major commercial partner, Futura is not putting any more money into this.

 

How it’s doing

With the condom very much on the backburner, Futura is focusing on two things at the minute: its ED gel pain relief gels.

A phase III study of MED2005 kicked off last October and more than 450 patients have been enrolled. Top-line data is expected before the year end.

“The study is going well and we’re looking forward to getting the results at the end of this year,” said chief executive James Barder.

As for TPR100, Futura’s partner Thornton & Ross applied for approval from UK regulators last summer. Discussions with officials are ongoing, but the company is hopeful of reaching a conclusion later this year.

Turning to the financials, the business posted a £5.89mln loss for the year ended December 31.

More importantly, having raised £5.85mln last November (and with cash resources of £9.16mln at the year-end), it has the financial runway to see it through to the data readout for its ED breakthrough. 

 

What the boss says

 

Blue sky

Looking ahead, there are a couple of key inflection points:

Headline results from the phase III trial of MED2005 which are due before the end of the year

A decision from UK regulators on TPR100,which Futura is hearing about later tin 2019

View full FUM profile View Profile

Futura Medical PLC Timeline

Newswire
December 17 2018

Related Articles

copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
Cyrptocurrencies
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
Medical scanner
February 08 2019
The company’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI (magnetic resonance imaging) and PRT (positron emission tomography) scanners
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use